Would using Obinutuzumab and Venetoclax second line after Bendamutine and Rituximab be a reasonable option for a patient with IGHV-unmutated CLL?

BR is still an option for frontline CLL, but since Venetoclax +obinutuzumab was approved for frontline therapy, the question you have posed is very relevant.

Now it is more important than ever, for the treating physicians to ask what is the therapeutic objective in each case? If we are dealing with ...